Prurigo Nodularis clinical trials at UCSF

2 in progress, 1 open to eligible people

Showing trials for

  • Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

    open to eligible people ages 18-80

    Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.

    San Francisco, California and other locations

  • PRISM Study-Pruritus Relief Through Itch Scratch Modulation

    Sorry, in progress, not accepting new patients

    To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.

    San Francisco, California and other locations

Last updated: